Related Experiment Videos
[Selected CD34+ cells transplantation: a primary clinical report]
1Bone Marrow Transplantation Center, North Taiping Hospital, Beijing 100039, China.
Zhonghua Yi Xue Za Zhi
|February 24, 2001
Summary
Selected CD34+ cell transplantation effectively reduces GVHD and tumor cell contamination, benefiting haploidentical and autologous transplants for various cancers.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- CD34+ cells are hematopoietic stem and progenitor cells.
- Ex vivo selection of CD34+ cells can deplete T-cells and tumor cells.
- This method holds potential for mismatched related donor allogeneic transplantation and autologous transplantation in tumor diseases.
Observation:
- Magnetic-activated cell sorting (CliniMACS) was used to isolate CD34+ cells from 19 patients undergoing allo- or auto-PB CD34+ cell transplantation.
- Grafts included cells from patients with lymphomas, multiple myelomas, SLE, Sjögren's syndrome, breast cancer, medulloblastoma, and haploidentical donors for leukemia.
Findings:
- Post-selection, CD34+ cell purity exceeded 97%.
- Extensive depletion of CD34-negative cells was achieved, including CD3+, CD4+, CD8+, and CD19+ cells.
- Overall survival was 68.4% (13/19) at a median follow-up of 11 months. Auto-CD34+ CT showed an 85.7% survival rate.
Implications:
- Selected CD34+ cell transplantation significantly reduces the incidence of Grade II or higher GVHD.
- This technique effectively depletes tumor cell contamination, making it beneficial for haploidentical or unrelated donor transplantation.
- The approach also shows promise for autologous transplantation in diverse tumor disorders.